Two Appalachian Congressmen Ask FDA To Reclassify OxyContin

PIKEVILLE, Ky. (AP) - Two Republican congressmen from Appalachia are asking the federal Food and Drug Administration to reclassify the powerful painkiller OxyContin.
Kentucky Congressman Hal Rogers and Virginia Congressman Frank Wolf want Oxycontin prescriptions to be restricted to people in
severe pain.
Currently, the drug also can be prescribed for moderate pain.
Rogers and Wolf sent a letter yesterday to the F-D-A citing
recent admissions that the company and three of its current and
former executives misled the public about the drug's risk of
F-D-A spokeswoman Sandy Walsh says the agency will review the
Purdue Pharma spokesman James Heins says the company doesn't
believe patient access to medicine should be restricted because of
misstatements made six or more years ago.
West Virginia Attorney General Darrell McGraw sued Purdue Pharma in 2001. McGraw accused the company of dishonestly marketing the painkiller in the state. Purdue-Pharma agreed to settle the case in 2004 for ten million dollars.

(Copyright 2007 by The Associated Press. All Rights Reserved.)

You must be logged in to post comments.

Password (case sensitive):
Remember Me:

Read Comments

Comments are posted from viewers like you and do not always reflect the views of this station.
  • by Disabled Location: Formerly KY on May 18, 2007 at 12:38 AM
    As a former Hospice RN, I saw the good aspects of oxycotin. It is a wonderful drug when used correctly. Not only does the drug company need to take responsibility but also the prescribing physician, he needs to follow up and monitor his patients well. Likewise, the patient has to take responsibility for himself to take the oxycotin as directed only. The patient can abuse any drug he wishes to if he doesn't do as directed.


2851 Winchester Rd. Lexington, Ky 40509 859-299-0411 - switchboard 859-299-2727 - newsroom
Register for Email
RSS Feeds
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 7564687 -
Gray Television, Inc.